Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Guillain-Barré syndrome after rituximab in a patient with idiopathic thombocytopenic purpura: a causal association?

× No keyword cloud information.

16 in total

1. Immunoglobulin for concurrent Guillain-Barré and immune thrombocytopenic purpura.

Authors: Lawrence A Zeidman; Christopher D Fahey; David L Grinblatt; Krisztina Harsanyi
Journal: Pediatr Neurol Date: 2006-01 Impact factor: 3.372

2. Worsening after rituximab treatment in anti-mag neuropathy.

Authors: Laura Broglio; Giuseppe Lauria
Journal: Muscle Nerve Date: 2005-09 Impact factor: 3.217

3. Guillain-Barré syndrome associated with idiopathic thrombocytopenic purpura.

Authors: O Combarros; J Calleja; L Hernández; J M Polo; J Berciano
Journal: J Neurol Neurosurg Psychiatry Date: 1991-07 Impact factor: 10.154

4. Guillain-Barré syndrome after combined CHOP and rituximab therapy in non-Hodgkin lymphoma.

Authors: Fabrizia Terenghi; Gianluca Ardolino; Eduardo Nobile-Orazio
Journal: J Peripher Nerv Syst Date: 2007-06 Impact factor: 3.494

5. Guillain-Barré syndrome and idiopathic thrombocytopenic purpura.

Authors: F Khaldi; A Larnaout; N Miladi; B Bennaceur
Journal: Can J Neurol Sci Date: 1990-02 Impact factor: 2.104

Review 6. Acute inflammatory sensorimotor polyradiculoneuropathy associated with immune thrombocytopenic purpura.

Authors: N Sato; T Kamata; N Akiyama; M Kuwana; T Kanda
Journal: J Intern Med Date: 2005-05 Impact factor: 8.989

7. Acute idiopathic polyneuritis and idiopathic thrombocytopenic purpura.

Authors: P T Gross
Journal: JAMA Date: 1980-01-18 Impact factor: 56.272

8. Concurrent immune thrombocytopenic purpura and Guillain-Barre syndrome in a patient with Hashimoto's thyroiditis.

Authors: Rajan Singh Kohli; Wissam Bleibel; Hani Bleibel
Journal: Am J Hematol Date: 2007-04 Impact factor: 10.047

Review 9. Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action.

Authors: M D Pescovitz
Journal: Am J Transplant Date: 2006-05 Impact factor: 8.086

Review 10. Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome.

Authors: Pieter A van Doorn; Liselotte Ruts; Bart C Jacobs
Journal: Lancet Neurol Date: 2008-10 Impact factor: 44.182

6 in total

Review 1. Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain-Barré syndrome.

Authors: Jane Pritchard; Richard Ac Hughes; Robert Dm Hadden; Ruth Brassington
Journal: Cochrane Database Syst Rev Date: 2016-11-15

Review 2. Immunoglobulin and Monoclonal Antibody Therapies in Guillain-Barré Syndrome.

Authors: Yusuf A Rajabally
Journal: Neurotherapeutics Date: 2022-06-01 Impact factor: 6.088

Review 3. Severe Guillain-Barré syndrome in a patient receiving anti-TNF therapy. Consequence or coincidence. A case-based review.

Authors: Bonifacio Alvarez-Lario; Rosa Prieto-Tejedo; María Colazo-Burlato; Jesús Macarrón-Vicente
Journal: Clin Rheumatol Date: 2013-05-11 Impact factor: 2.980

4. Delayed-onset flaccid paralysis related to west Nile virus reactivation following treatment with rituximab: a case report.

Authors: Asaf Honig; Dimitrios Karussis
Journal: BMC Res Notes Date: 2014-11-26

5. Refractory pemphigus vulgaris successfully treated with ofatumumab.

Authors: Daniel M Klufas; Erin Amerson; Olivia Twu; Leon Clark; Kanade Shinkai
Journal: JAAD Case Rep Date: 2020-06-04

Review 6. Biological Drugs in Guillain-Barré Syndrome: An Update.

Authors: Nazgol Motamed-Gorji; Nassim Matin; Omidreza Tabatabaie; Piero Pavone; Catia Romano; Raffaele Falsaperla; Giovanna Vitaliti
Journal: Curr Neuropharmacol Date: 2017 Impact factor: 7.363

6 in total